Mesoblast Ltd., of Melbourne, Australia, said its licensee, JCR Pharmaceuticals Co. Ltd., of Ashiya, Japan, received full approval from Japanese regulators for Temcell HS injection (JR-031), an allogeneic mesenchymal stem cell product, for treating children and adults with acute graft-vs.-host disease.